Summary
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in
combination with tiragolumab compared with durvalumab in participants with locally
advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at
least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had
radiographic disease progression.